for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dynavax Technologies Corporation

DVAX.OQ

Latest Trade

5.84USD

Change

0.10(+1.66%)

Volume

132,850

Today's Range

5.70

 - 

5.95

52 Week Range

2.60

 - 

11.43

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Dynavax Announces Third Quarter 2019 Financial Results

Nov 6 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.49.SEES FY 2019 REVENUE $34 MILLION TO $36 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.REVENUE EXPECTATION OF $34 MILLION-$36 MILLION FOR FULL YEAR 2019.QTRLY NET PRODUCT REVENUE $10.2 MILLION VERSUS $1.5 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $174.9 MILLION AT SEPTEMBER 30, 2019.EXPECTS HEPLISAV-B NET PRODUCT REVENUE OF $34-$36 MILLION FOR THE FULL YEAR 2019.Q3 REVENUE VIEW $10.3 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $36.9 MILLION -- REFINITIV IBES DATA.

Dynavax Technologies Announces Proposed Public Offering Of Common Stock, Non-Voting Preferred Stock And Warrants To Purchase Common Stock

Aug 7 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX TECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK, NON-VOTING PREFERRED STOCK AND WARRANTS TO PURCHASE COMMON STOCK.DYNAVAX TECHNOLOGIES CORP - INTENDS TO OFFER AND SELL AN AGGREGATE OF UP TO $60.0 MILLION OF SHARES OF ITS COMMON STOCK.DYNAVAX TECHNOLOGIES CORP - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ACTIVITIES ASSOCIATED WITH ONGOING COMMERCIALIZATION OF HEPLISAV-B.

Dynavax Technologies Q2 Loss Per Share $0.66

Aug 7 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.66.Q2 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.UPDATED NET PRODUCT REVENUE GUIDANCE OF $32-$36 MILLION FOR FULL YEAR 2019.COMPANY IS EXPLORING STRATEGIC ALTERNATIVES FOR ITS IMMUNO-ONCOLOGY PORTFOLIO.IN QUARTER RECOGNIZED RESTRUCTURING CHARGES OF $8.8 MILLION AND REMAINING $0.6 MILLION IS EXPECTED TO BE RECOGNIZED BY END OF 2019.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $140.5 MILLION AT JUNE 30, 2019..

Dynavax Announces Strategic Restructuring To Focus On Its Vaccine Business

May 23 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS VACCINE BUSINESS.DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS VACCINE BUSINESS.DYNAVAX TECHNOLOGIES CORP - COMPANY WILL ALIGN ITS RESOURCES TO FOCUS ON HEPLISAV-B COMMERCIALIZATION.DYNAVAX TECHNOLOGIES CORP - EDDIE GRAY, CEO, TO RETIRE.DYNAVAX TECHNOLOGIES CORP - EDDIE GRAY, CEO, TO RETIRE.DYNAVAX TECHNOLOGIES CORP - WILL EXPLORE STRATEGIC ALTERNATIVES FOR ITS IMMUNO-ONCOLOGY PROGRAMS.DYNAVAX TECHNOLOGIES CORP - WORKFORCE REDUCTION IS EXPECTED TO REDUCE COMPENSATION AND BENEFITS COST BY APPROXIMATELY $16 MILLION DOLLARS ANNUALLY.DYNAVAX TECHNOLOGIES CORP - WILL CONDUCT A SEARCH FOR COMPANY'S NEXT CEO AND WILL CONSIDER BOTH INTERNAL AND EXTERNAL CANDIDATES..DYNAVAX TECHNOLOGIES CORP - IS ELIMINATING APPROXIMATELY 82 CURRENT POSITIONS.DYNAVAX TECHNOLOGIES - RESTRUCTURING COSTS AND RETIREMENT COSTS, SEVERANCE COSTS, ARE EXPECTED TO BE APPROXIMATELY $5.5 MILLION.DYNAVAX TECHNOLOGIES - IS ELIMINATING ABOUT 37% OF ITS CURRENT U.S. WORKFORCE.DYNAVAX - WILL BE RESPONSIBLE FOR SOME WIND-DOWN COSTS, COMMITTED CONTRACTUAL COSTS FOR IMMUNO-ONCOLOGY PROGRAMS THAT WILL RUN THROUGH Q2 NEXT YEAR.DYNAVAX TECHNOLOGIES - ESTIMATES OPERATING EXPENDITURES RELATED TO EXTERNAL ONCOLOGY COSTS WILL BE REDUCED BY ABOUT $8 MILLION PER QUARTER VERSUS MARCH QUARTER.DYNAVAX TECHNOLOGIES - AS OF MARCH 31, REPORTED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $183.2 MILLION..

Dynavax Reports Q1 Loss Per Share $0.62

May 8 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.65 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $183.2 MILLION AT MARCH 31, 2019.

Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist

April 2 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX PRESENTS PHASE 1B DATA ON INHALED DV281 TLR9 AGONIST AT THE 2019 AACR ANNUAL MEETING.DYNAVAX TECHNOLOGIES CORP - TARGET ENGAGEMENT WAS OBSERVED AT ALL DOSE LEVELS.DYNAVAX TECHNOLOGIES - INHALED DV281 IN COMBINATION WITH SYSTEMIC NIVOLUMAB WAS WELL TOLERATED IN A POPULATION OF HEAVILY PRE-TREATED NSCLC PATIENTS.DYNAVAX TECHNOLOGIES CORP - NO IMMUNE-RELATED ADVERSE EVENTS SUCH AS PNEUMONITIS HAVE BEEN REPORTED..

Dynavax - Due To Sciabacucchi Decision, Do Not Currently Intend To Enforce Foregoing Federal Forum Selection Provision Unless Decision Reversed

March 1 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX - DUE TO SCIABACUCCHI DECISION, DO NOT CURRENTLY INTEND TO ENFORCE FOREGOING FEDERAL FORUM SELECTION PROVISION UNLESS DECISION REVERSED.

Dynavax Technologies Expects Sales Of Heplisav-B For Quarter Ended Dec 31 To Be No Less Than $3.7 Mln

Jan 11 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX TECHNOLOGIES - EXPECTS SALES OF HEPLISAV-B FOR FISCAL QUARTER ENDED DEC 31, 2018 TO BE NO LESS THAN $3.7 MILLION.

Sam's Club And Dynavax Technologies Announce Collaboration To Make Hepatitis B Vaccine

Jan 8 (Reuters) - Dynavax Technologies Corp <DVAX.O>::SAM’S CLUB AND DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCE COLLABORATION TO MAKE HEPLISAV-B® [HEPATITIS B VACCINE (RECOMBINANT), ADJUVANTED] AVAILABLE TO SAM’S CLUB PATIENTS.DYNAVAX TECHNOLOGIES - CO, SAM'S CLUB TEAMED UP TO INTRODUCE HEPLISAV-B INTO SAM'S CLUB RETAIL PHARMACIES NATION-WIDE IN U.S..

Dynavax Technologies-AstraZeneca Informed Co Initial High-Level Results From Phase 2A Study Indicate Azd1419 Treatment Did Not Meet Primary Endpoint

Nov 29 (Reuters) - Dynavax Technologies Corp <DVAX.O>::DYNAVAX TECHNOLOGIES - ASTRAZENECA INFORMED CO INITIAL HIGH-LEVEL RESULTS FROM PHASE 2A STUDY INDICATE AZD1419 TREATMENT DID NOT MEET PRIMARY ENDPOINT.DYNAVAX TECHNOLOGIES CORP - ASTRAZENECA WILL NOW REVIEW FULL DATA BEFORE DECIDING ON NEXT STEPS FOR AZD1419 PROGRAM.DYNAVAX TECHNOLOGIES SAYS AZD1419 TREATMENT APPEARED TO BE SAFE & WELL TOLERATED & STUDY CONFIRMED ACTIVATION OF TLR9 PATHWAY - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up